ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 839

Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis

Joshua Baker1, Bryant England 2, Michael George 3, Grant Cannon 4 and Ted Mikuls 5, 1University of Pennsylvania, Philadelphia, PA, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, 3University of Pennsylvania, Philadelphia, 4Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, 5VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARP Annual Meeting 2019

Keywords: Diabetes, Disease Activity and obesity, Rheumatoid arthritis (RA)

Session Information

Date: Sunday, November 10, 2019

Title: 3S078: RA – Diagnosis, Manifestations, & Outcomes I: Pulmonary & Other Comorbidities (839–844)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Rheumatoid arthritis is associated with a higher risk of diabetes mellitus (DM) and cardiovascular disease. While disproportional obesity and visceral fat accumulation may contribute to a higher incidence of DM, the systemic inflammatory disease may directly lead to insulin resistance and promote the development of cardiometabolic disease. Our aim was to evaluate associations between disease activity (including evaluation of specific cytokines and chemokines) among veterans with RA and determine independent associations with incident DM incidence in a longitudinal cohort.

Methods: Participants were enrollees in a multicenter, longitudinal observational cohort of US veterans with RA. Baseline demographics, comorbidities, body mass index (BMI), ACPA status, disease activity (DAS28-CRP), and active therapies were derived from query of the electronic medical record and registry data. Therapies and disease activity were assessed as time-varying covariates in initial models. Seventeen cytokines and chemokines were measured in banked serum obtained at the time of enrollment in a subset of partiipants using a bead-based multiplex assay. Cytokine/chemokine values were log-adjusted and standardized (all values are per 1 SD). Incident DM was defined as the presence of a new diagnosis code at any time in follow-up (following at least 12 months of follow up without a code).  Multivariable Cox proportional hazards models evaluated associations between clinical factors and incident DM. Independent associations between specific cytokines and chemokines were assessed adjusting for age, sex, race, smoking, and medication use at baseline.

Results: Among 1,918 RA patients without prevalent DM, there were 239 cases of incident DM over 9,055 person-years of follow-up. Patients with high disease activity, obese BMI, older age, male sex, and non-white race were at the greatest risk for incident DM (Table 1). Those using TNFi were at significantly lower risk. In models adjusting for demographics, smoking, and baseline medication use, two chemokines evaluated were significantly associated with the incidence of DM (per 1 SD). These were Macrophage Inhibitory Protein (MIP)-1b [HR 1.20 (95% CI 1.04, 1.39) p=0.01] and Interleukin(IL)-8 [HR 1.16 (95% CI 1.02, 1.33) p=0.02] (Figure). Higher quartiles of MIP-1b and IL-8 were associated with incident DM in a dose-dependent manner (Table 2). These associations were not attenuated with adjustment for DAS28-CRP.

Conclusion: Older age, male sex, higher disease activity, greater BMI, and elevated levels of the chemokines MIP-1b and IL-8 are associated with incident DM in veterans with RA.  Notably, levels of IL-1, TNF-a, and IL-6 were not significantly associated with incident DM in this population although TNFi use was predictive of future DM. Future study may help to determine if other targeted treatments in at-risk individuals could help to prevent the development of DM in patients with RA.


cytkines and DM_Table 1

Table 1: Association between clinical factors and the risk of incident diabetes. Disease activity and medications evaluated as time-varying covariates.


cytokines and DM_Table 2

Table 2: Cox proportional hazards models assessing associations between quartile of MIP-1 and IL-8 and incident diabetes -2 separate models-.


MIP-1 IL8 graph

Figure: Hazard ratios for the risk of incident diabetes among rheumatoid arthritis patients by individual cytokine concentrations -per 1 SD- adjusting for age, sex, race, current smoking, baseline body mass index, and baseline medication use -each represents a separate model-.


Disclosure: J. Baker, Bristol-Myers Squib, 5, Burns-White LLC, 5, Myriad RBM, 2; B. England, None; M. George, AbbVie, 5, Bristol Myers Squibb, 2, Bristol-Myers Squibb, 2; G. Cannon, Amgen, 2; T. Mikuls, BMS, 2, Horizon, 2.

To cite this abstract in AMA style:

Baker J, England B, George M, Cannon G, Mikuls T. Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/disease-activity-cytokine-profiles-and-the-risk-of-incident-diabetes-in-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disease-activity-cytokine-profiles-and-the-risk-of-incident-diabetes-in-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology